bpc 157 immunogenicity BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded NBC News | The claims

The pleiotropic MET receptor network: circuit development and the neural-medical interface of autism

The result is a quadruple agonist approach to metabolic optimization that goes beyond what even the most aggressive single-agent protocols can deliver

PMID 34170647

Not FDA approved

However, due to poor metabolic stability of angiotensin IV and many AnglV analogues, the inability of early analogues to penetrate the blood brain baixier, and the failure to identify the AT4 receptor, no pharmaceutical company has moved forward with their development

As the systematic review noted: No clinical safety data were found. When the FDA says insufficient evidence, they mean itwe literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road